Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA turned down its marketing application. The negative outcome for the review isn’t ...
Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote from an FDA advisory committee at its meeting last week, but the same panel had bad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback